Inside Bell Labs: Excitement On The Bench; Concern on High

Inside Bell Labs: Excitement On The Bench; Concern On High AUTHOR: SHARON BEGLEY Date: September 05, 1988 Researchers have never felt freer, but some lab heads and a prominent former manager see major changes since divestiture The stockholder was annoyed. Why, he demanded, was AT&T paying Thomas Gradel, a middle-aged scientist, to tromp around the Jungles of Brazil studying ants, when the dollars could be better used to fatten up Bell’s notoriously meager dividends? The irate stoc

Written bySharon Begley
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Inside Bell Labs: Excitement On The Bench;

The stockholder was annoyed. Why, he demanded, was AT&T paying Thomas Gradel, a middle-aged scientist, to tromp around the Jungles of Brazil studying ants, when the dollars could be better used to fatten up Bell’s notoriously meager dividends? The irate stockholder might equally well have asked about J. Anthony Tyson the astronomer on AT&T’s payroll who ricochet, between observatories in Hawaii and Chile to peer at galaxies at the far reaches of the universe. The answer is that their employer believes in the promise of long-term payoffs provided by basic research endeavors such theirs, despite the long-term investment they require.

That, of course, has been the conventional wisdom about Bell Labs. For 62 years the Labs has been the premier corporate research facility engaging in unfettered basic and applied research.

Gradel and Tysons predecessors spawned sound motion pictures, the transistor, the solar cell, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies